SRPT
Sarepta Therapeutics Inc
17.50$
-0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5.0% | -1.2% | +6.2% | +5.1% | +10.1% | -12.6% | +6.2% | -5.1% | -4.1% | -5.1% | +0.3% | |
| – | +5.2% | -4.4% | +8.9% | +0.1% | +14.5% | -20.9% | +9.2% | +2.5% | -6.8% | -9.0% | -3.7% | |
| – | -20.9% | -0.3% | -10.2% | -48.4% | +457.5% | -78.2% | +112.0% | +20.1% | +30.7% | -42.0% | +23.0% | |
| – | -3.3% | -17.0% | +5.0% | -17.9% | +13.1% | -61.4% | +53.1% | +6.4% | +10.4% | -30.5% | +20.7% | |
| – | +23.3% | -4.0% | -6.5% | +31.5% | +25.9% | +11.5% | -15.9% | -11.2% | -4.1% | +5.4% | -11.9% | |
| – | +32.3% | +15.7% | +30.1% | +16.5% | +32.5% | +25.5% | +5.6% | +8.4% | -15.1% | +9.4% | -9.7% | |
| – | +51.9% | -2.3% | -2.3% | -2.4% | -2.5% | -2.6% | +16.5% | -2.7% | -2.5% | +8.4% | -2.5% | |
| – | +2.6% | -5.9% | +3.7% | +1.3% | +2.4% | -4.6% | 0.0% | -6.4% | +1.6% | -24.2% | -0.8% | |
| – | +45.0% | -6.9% | +13.1% | +1.6% | +4.6% | -17.2% | +51.9% | +0.2% | +18.9% | -54.4% | +0.8% | |
| – | -61.7% | -14.4% | -13.3% | +0.1% | -85.3% | – | – | – | +12.0% | – | – | |
| – | +87.5% | -44.5% | +17.3% | +10.6% | +80.5% | -27.2% | -12.4% | -31.2% | +198.7% | -74.9% | -27.6% | |
| – | -8.4% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | -9.2% | -19.9% | +1.1% | +1.1% | |
| – | +12.4% | +11.9% | +12.1% | +13.4% | +25.1% | -25.2% | +18.8% | -2.7% | -13.6% | +32.0% | +1.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.8% | -6.1% | +0.0% | +1.3% | +8.0% | -10.2% | +9.5% | -6.0% | +4.5% | +16.3% | -13.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.